Eliminating agent for activated oxygen and free radicals
US6197806A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Dec 18, 1996 |
| Grant date | Mar 6, 2001 |
| Priority date | — |
| Expiry date | Dec 18, 2016 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P39/06
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Hydantoin derivatives for eliminating free radicals and active oxygen which can be easily made into pharmaceutical preparations, show little, if any side effects, and are capable of being administered by the oral route. The pharmaceutical compositions for eliminating the active oxygen and the free radicals contain at least one hydantoin derivative represented by the following formula (I): ##STR1## wherein each of R.sub.1 and R.sub.2, which may be the same or different, represents hydrogen, an alkyl group or a cycloalkyl group; and each of X and Y, which may be the same or different, represents hydrogen, a hydroxyl group, an alkyl group or an alkoxy group, or X and Y together represent an oxo group. The hydantoin derivatives which have an action of eliminating the active oxygen and the free radicals are, accordingly, useful as pharmaceutical agents for treating a variety of diseases in which active oxygen and free radicals are involved or play a detrimental role. Exemplary of the diseases which may be treated are myocardial infarction, reperfusion disturbance, autoimmune diseases, fibrosis, pulmonary diseases, dermatological diseases, arthropathy, side effects of anticancer agents, …
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.